Grace Goldstein, Chief Operating Officer of the Carcinoid Cancer Foundation, will speak at the Open Public Hearing segment during the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee Meeting on April 12, 2011 in Silver Spring, Maryland.
During the morning session the committee will discuss the application submitted by Novartis Pharmaceuticals Corporation for the drug Afinitor (everolimus). The proposed use for this product is for the treatment of patients with advanced neuroendocrine tumors (NETs) of gastrointestinal, lung or pancreatic origin. During the afternoon session, the committee will discuss the application submitted by C.P. Pharmaceuticals International C.V., represented by Pfizer Inc., for the drug Sutent (sunitinib malate). The proposed use for this product is for the treatment of unresectable pancreatic neuroendocrine tumors (PNETs). To read more about the meeting, CLICK HERE.
The results of two separate Phase III clinical trials about the drugs were published in the New England Journal of Medicine, February 10, 2011, Vol. 364 No. 6: http://www.nejm.org/toc/nejm/364/6.
Carcinoid/NET cancer patients, caregivers, physicians, or other healthcare professionals who would like to share their point of view about these drugs with Ms. Goldstein so that she can incorporate additional information into her presentation for the FDA Oncologic Drugs Advisory Committee Meeting should contact her by e-mail at ggoldstein@carcinoid.org or by telephone at 888-722-3132, Eastern Time.
